CD7 and immunodeficiency disease: Furthermore, CAR-T/NK targeting CD7 will clear CD7-positive normal T/NK cells in vivo, HSCT is usually required after CAR-T therapy; otherwise, the treatment causes severe immunodeficiency and potentially life-threatening infection by pathogenic microorganisms.